克癌胶囊抗肝癌作用的实验研究

Experimental Research on Effect of Anti-Tumor with Ke'ai Capsule(克癌胶囊)

目的:通过实验方法揭示软坚散结方药——克癌胶囊的抗肝癌作用。方法:分体外实验和体内实验,前者包括克隆形成法、活细胞计数法和 NAG 微量酶反应法;后者主要观察荷瘤小鼠移植瘤的生长和小鼠的存活时间。结果:体外实验表明克癌胶囊能明显抑制人肝癌细胞 BEL-7402生长,ED_(50)在克隆形成法为38.5mg/L,活细胞计数法为54.0mg/L;与5-Fu 有显著的协同作用(P<0.05)。体内实验表明剂量为1.8、3.6、7.2g·kg^(-1)·d^(-1),对 BALB/C小鼠实体瘤(HepA)的抑瘤率(%)平均分别为16.6(P>0.05)、32.4(P<0.05)、49.6(P<0.01);生命延长率(%)平均分别为109(P>0.05)、135(P<0.05)、159(P<0.01),剂量与效应呈直线相关;剂量为3.6、7.2g·kg^(-)1·d^(-1),对 BALB/C 小鼠腹水癌(HepA)产生的抑制率(%)平均分别为14.2(P>0.05)、31.0(P<0.05);生命延长率(%)平均分别为110(P>0.05)、135(P<0.05)。结论:克癌胶囊有抗肝癌效果,与化疗药有协同增效作用。

Objective:To prove the effects of softening and resolving hard mass,a principle of TCM on hepatoma with Ke'ai capsule(KAC,an anti-tumor drug).Methods:The experiments in vitro included clonal formation,living cellular count and N-acetyl-glucosamine trace-enzyme reactions,and experiments in vivo included tumor growth and living time of the mice beating tumor were detected.Results:KAC had an obvious inhibition activity on the human hepatoma cells,BEL- 7402,in vitro.With clonal formation and living cellular count the ED_(50) was 38.5mg/L and 54.0mg/L,respectively. While a cooperative action was observed in KAC and 5-FU(CDI<0.85,P<0.01).In vivo,with different dosage of KAC,1.8,3.6 and 7.2(g/kg per day),mean inhibition growth rate of tumor(HepA)in BALB/c mice was 16.6%(P >0.05),32.0%(P<0.05),and 49.8%(P<0.01),and the rate(T/C%)of delaying survival time of the mice bearing tumor(HepA)was 109%(P>0.05),135%(P<0.05)and 159%(P<0.01),respectively,and there were linear relations(P<0.01)between the dosages and the effects.The mean ratio of delaying survival time of the mice bearing ascites(HepA)with doses 3.6 and 7.2(g/kg,per day)was 110%(P>0.05)and 135%(P<0.05),respec- tively.Conclusion:KAC had the effects on hepatoma certainly and is worth to research further.